Oligo Synthesis : CEPs
Prices quoted are for single packs only. For multiples of the same product please request a quote. Some of Glen"sproductsarehazardousandmay be subject to additional shipping charges. Full product information is available onGlen Research"s website.
dT-PACE Phosphoramidite
dT-PACE Phosphoramidite
Glen Research
| Catalogue No. | Description | Pack Size | Price | Qty |
|
|---|---|---|---|---|---|
| 10-1170-02 | dT-PACE Phosphoramidite | 0.25g | £100.00£95.00Offer until : 31-Mar-2021Offer Code : GLEN5View Offer | Quantity | Add to Order |
| 10-1170-05 | dT-PACE Phosphoramidite | 0.5grams | £200.00£190.00Offer until : 31-Mar-2021Offer Code : GLEN5View Offer | Quantity | Add to Order |
Related products
dT-PACE Phosphoramidite
dT-PACE Phosphoramidite
Glen Research
| dT-PACE Phosphoramidite |
Catalog Number: 10-1170-xx
Description: dT-PACE Phosphoramidite
| 5"-Dimethoxytrityl-2"-deoxyThymidine,3"-O-(N,N-diisopropylamino)-phosphinyl-1,1-dimethyl-2-cyanoethyl acetate | ||
| Formula: C44H55N4O9P | M.W.: 814.90 | F.W.: 345.22 |
Diluent: Anhydrous Acetonitrile |
| Coupling: 33 minutes with 1H-Tetrazole Activator.Synthesis: Oxidize before capping. Use either low water, low iodine oxidizer (Cat.# 40-4032-xx) or 10-camphorsulfonyloxaziridine (CSO) in acetonitrile. When CSO is used, extend the oxidation time to 3 minutes. Use 0.5M CSO when oxidizing mixed PACE/phosphodiester linkages. When oxidizing only PACE linkages, 0.1 M CSO can be used. For Cap Mix B, use 6.5% DMAP in THF (Cat.# 40-4020-xx). An example of a PACE cycle for AB synthesizers can be seen at:http://www.glenresearch.com/Technical/PACE_cycle.pdf |
| Deprotection: Pretreat synthesis column with 1.5% DBU in anhydrous acetonitrile for 60 minutes (syringe method). Wash with acetonitrile and dry with argon. Deprotect with 40% Methylamine for 20 minutes at 55°C. |
| Storage: Freezer storage, -10 to -30°C, dry |
| Stability in Solution: 2-3 days |
| Please Note: This product is covered by US Patents 6,693,187 and 7,067,641, patents pending and foreign counterparts owned by Lievre Cornu. Purchase of all or any of these products includes a limited license to use the product solely in the manufacture of oligonucleotides for RESEARCH USE ONLY and its use is not authorized nor intended for diagnostic or therapeutic use. |
| Please see Terms and Conditions of Use |
PACE PHOSPHORAMIDITES
Phosphonoacetate (PACE) modified oligonucleotides show great potential as biological modifiers in a wide variety of research applications. PACE monomers are part of a family of Phosphonocarboxylate monomers. The monomers can be easily incorporated into complex oligonucleotides and are compatible with a wide variety of other sugar or heterobase modifications. PACE DNA can be conjugated through the carboxylic acid functional group. They have been shown to be active in siRNA duplexes and accelerate the initial rate of cleavage by RNase H-1 when incorporated with phosphorothioates. However, the most interesting observation to date is that they exhibit an unprecedented enhancement in penetration of cultured cells.
The phosphonoacetates are fully soluble in acetonitrile at a recommended concentration of 0.1M and are compatible with standard DNA synthesizers. A recommended coupling time of 33.3 minutes with 1H-Tetrazole is necessary when using the standard protocol. A modified LV cycle for AB instruments that reduces coupling time to 15 minutes with 1H-Tetrazole is available on our website. Oxidation must precede capping in the synthesis cycle. Reagents for oxidation depend on the type of synthesis. For fully modified oligos, we recommend the non-aqueous oxidizer camphorsulfonyloxaziridine (CSO) as a 0.1M solution. For mixed phosphodiester and phosphonoacetate modified oligos, a 0.5M CSO solution with a minimum oxidation time of 3 minutes is recommended. Low water oxidizer, 40-4032, is an alternative oxidizing reagent although it has been reported that this can result in conversion of a small percentage of the phosphonoacetate to the phosphodiester. We also recommend the use of the Cap Mix B with DMAP (40-4020) instead of the standard Cap Mix B containing 1-Methylimidazole.
The standard protocol for cleavage and deprotection requires a two step method with pretreatment using 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) and subsequent cleavage using methylamine. The DBU is used to deprotect the dimethylcyanoethyl (DMCE) protecting groups and to prevent alkylation of the bases during deprotection. Cleavage with 40% methylamine in water is recommended and we have also had good results when using AMA deprotection.
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
dT-PACE Phosphoramidite
dT-PACE Phosphoramidite
Glen Research
Material Safety Data Sheet
| Glen Report 20.2: Phosphonoacetate (PACE) Oligonucleotides |
| Glen Report 20.2: Synthesis, Cleavage and Deprotection of PACE Oligonucleotides |
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
dT-PACE Phosphoramidite
dT-PACE Phosphoramidite
Glen Research
Glen Report 30.1 Significant Improvement of CRISPR Specificity with 2"-OMe-PACE Modifications
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
dT-PACE Phosphoramidite
dT-PACE Phosphoramidite
Glen Research
DILUTION/COUPLING DATA
The table below shows pack size data and, for solutions, dilutions and approximate couplings based on normal priming procedures. Please link formore detailed usage informationwith the various synthesizers.
| ABI 392/394 | |||||||||
| Cat.No. | PackSize | Grams/Pack | 0.1M Dil.(mL) | LV40 | LV200 | 40nm | 0.2µm | 1µm | 10µm |
| Approximate Number of Additions | |||||||||
| 10-1170-02 | 0.25grams | .25grams | 3.07 | 89 | 53.4 | 33.38 | 24.27 | 17.8 | 4.45 |
| 10-1170-05 | 0.5grams | .5grams | 6.14 | 191.33 | 114.8 | 71.75 | 52.18 | 38.27 | 9.57 |
| 10-1170-10 | 1.0gram | 1grams | 12.27 | 395.67 | 237.4 | 148.38 | 107.91 | 79.13 | 19.78 |
| Expedite | |||||||||
| Cat.No. | PackSize | Grams/Pack | Dilution(mL) | Molarity | 50nm | 0.2µm | 1µm | 15µm | |
| Approximate Number of Additions | |||||||||
| 10-1170-02 | 0.25grams | .25grams | 4.58 | .07 | 85.2 | 53.25 | 38.73 | 5.33 | |
| 10-1170-05 | 0.5grams | .5grams | 9.16 | .07 | 176.8 | 110.5 | 80.36 | 11.05 | |
| 10-1170-10 | 1.0gram | 1grams | 18.32 | .07 | 360 | 225 | 163.64 | 22.5 | |
| Beckman | |||||||||
| Cat.No. | PackSize | Grams/Pack | Dilution(mL) | Molarity | 30nm | 200nm | 1000nm | ||
| Approximate Number of Additions | |||||||||
| 10-1170-02 | 0.25grams | .25grams | 4.58 | .07 | 86.8 | 54.25 | 39.45 | ||
| 10-1170-05 | 0.5grams | .5grams | 9.16 | .07 | 178.4 | 111.5 | 81.09 | ||
| 10-1170-10 | 1.0gram | 1grams | 18.32 | .07 | 361.6 | 226 | 164.36 | ||
If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200
AthensResearch&Technology公司位于美国乔治亚州雅典市，从1986年以来一直致力于纯化高纯度，高活性的人类蛋白质和开发这些蛋白的多克隆抗血清。我们的常规产品包括丝氨酸蛋白酶、蛋白酶抑制剂、中性粒细胞酶、载脂蛋白、脂蛋白，血小板蛋白、转铁蛋白、免疫球蛋白等。二十年多年来，世界各地的研究人员都在使用我们公司的产品。在炎症、冠状动脉疾病、自身免疫性疾病、癌症、老年痴呆症等等研究的主要科学出版物中都能看到引用我们公司的产品。我们提供优质，可靠的产品和出色的客户服务。我们期待着您的业务。如果需要定制研究服务，AthensResearch&Technology公司能够根据您的项目要求提供无与伦比的试剂。
公司主要产品：一、凝血因子相关系列产品：包括多款从人血浆、血小板中分离纯化的凝血因子相关蛋白。二、酶及抑制剂系列产品：包括多款从人血浆、红细胞分离纯化的a-抗糜蛋白酶、a1/2抗胰蛋白酶、抗凝血酶、C1酯酶抑制因子、Calpain-1等酶及其抑制剂产品。三、免疫球蛋白系列产品：包括多款从人血浆、骨髓瘤、初乳以及狗和小鼠血浆中分离纯化的免疫球蛋白产品。四、脂蛋白及载脂蛋白系列产品：包括包括多款从人血浆中分离纯化的载脂蛋白及脂蛋白（高密度、中等密度、低密度、极低密度脂蛋白）产品。五、低内毒素蛋白系列产品：包括多款适宜于细胞培养的低内毒素脂蛋白、免疫球蛋白及转铁蛋白产品。六、乳蛋白系列产品：包括从人乳中分离纯化的乳白蛋白、乳铁传递蛋白及分泌型免疫球蛋白A。七、中性粒细胞源蛋白系列产品：包括多款纯化分离自人中性粒细胞的Azurocidin 、CathepsinG及Lactoferrin等蛋白产品。八、血小板相关系列产品：包括纯化分离自人血小板的血小板因子4及凝血酶致敏蛋白。九、转铁蛋白及脱铁转铁蛋白（APOTRANSFERRINS）系列产品：包括多款纯化分离自人、大小鼠、狗及食蟹猴血浆中的转铁蛋白/脱铁转铁蛋白，可应用于细胞或组织培养。十、抗体系列产品：包括多款兔、大鼠、羊源的多克隆抗体产品。
ebiomall.com
